Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

BACKGROUND Mutations of the p53 gene are associated with a poor prognosis in several types of cancer. We investigated the prognostic importance of p53 mutations in patients with aggressive B-cell lymphoma. METHODS We examined the relation between the presence or absence of a detectable p53 mutation in lymphoma cells and the response to chemotherapy and overall survival in 102 previously untreated patients with aggressive B-cell lymphoma. Mutations of the p53 gene were identified by polymerase-chain-reaction-mediated analysis of single-strand conformation polymorphisms and by direct sequencing. RESULTS Of 102 cases of aggressive B-cell lymphoma, 22 (22 percent) involved p53 mutations. The rate of complete remission was significantly lower in patients with a tumor carrying a p53 mutation (6 of 22 patients, 27 percent) than in those with the wild-type p53 gene (61 of 80 patients, 76 percent) (P<0.001). Overall survival was significantly lower among patients with p53 mutations than among those with the wild-type p53 gene; the Kaplan-Meier estimates of survival at five years were 16 percent and 64 percent, respectively (P<0.001). Multivariate analysis incorporating prognostic factors from the international prognostic index demonstrated that p53 mutations had independent effects on the rates of complete remission and survival. When we categorized patients according to the international prognostic index, we found no effect of p53 mutations in patients in the groups at high-intermediate and high risk. However, these mutations were significantly associated (P< 0.001) with low rates of complete remission (33 percent vs. 91 percent) and survival (27 percent vs. 81 percent at five years) in the groups at low and low-intermediate risk. CONCLUSIONS Mutations of the p53 gene are associated with a poor prognosis in patients with aggressive B-cell lymphoma.

[1]  D. Cox.  Regression Models and Life-Tables , 1972 .

[2]  K. Hayashi,et al.  Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. , 1992, Blood.

[3]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[4]  T. Sekiya,et al.  Allele-specific polymerase chain reaction: a method for amplification and sequence determination of a single component among a mixture of sequence variants. , 1991, Analytical biochemistry.

[5]  B. Vogelstein,et al.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. , 1990, Cancer research.

[6]  E. Jaffe,et al.  Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[8]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[9]  F. Cabanillas,et al.  Combination chemotherapy ("CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma. , 1977, Blood.

[10]  G. Pinkus,et al.  Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.

[11]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[12]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[13]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[14]  M. Ladanyi,et al.  Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. , 1994, The New England journal of medicine.

[15]  M. Haas,et al.  Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines , 1990, Molecular and cellular biology.

[16]  S. Jagannath,et al.  Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H A Erlich,et al.  Generation of single-stranded DNA by the polymerase chain reaction and its application to direct sequencing of the HLA-DQA locus. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  S. Tucker,et al.  A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Pasmantier,et al.  Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.

[20]  D. Weisenburger,et al.  Chromosomal abnormalities in untreated patients with non-Hodgkin's lymphoma: associations with histology, clinical characteristics, and treatment outcome. The Nebraska Lymphoma Study Group. , 1990, Blood.

[21]  Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. , 1981 .

[22]  I. Pastan,et al.  Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. , 1992, Science.

[23]  B. Coiffier,et al.  Prognosis of aggressive lymphomas: a study of five prognostic models with patients included in the LNH-84 regimen. , 1989, Blood.

[24]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[25]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[26]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[27]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[29]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[30]  David R. Cox.  The analysis of binary data , 1970 .

[31]  B. Vogelstein.  A deadly inheritance , 1990, Nature.

[32]  J. Eyfjörd,et al.  Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. , 1993, Cancer research.

[33]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[34]  D. Housman,et al.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents , 1993, Cell.

[35]  W. Wilson,et al.  Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. , 1997, Blood.

[36]  M. Kikuchi,et al.  Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M. , 1988, Journal of Clinical Oncology.

[37]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[38]  J. Armitage,et al.  Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Connors,et al.  MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.

[40]  D. Weisenburger,et al.  The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[42]  C. Coltman,et al.  Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.

[43]  C. Pui,et al.  High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. , 1987, Blood.